Neurol. praxi. 2014;15(6):333-337

Fingolimod in clinical practice: case reports

doc. MUDr. Radomír Taláb, CSc.1, MUDr. Marika Talábová2
1 Neurologie &ndash, RS centrum s.r.o., Hradec Králové
2 Neurologická klinika LF UK a FN Hradec Králové

Treatment escalation in multiple sclerosis (MS) can be achieved by the use of fingolimod that represents an advancement in treating MS not only due to its mechanism of action, but also because of its dosage form (tablets). Fingolimod was the first oral medication for the treatment of relapsing-remitting MS (RRMS). It is the first sphingosine-1-phosphate (S1P) receptor modulator. Fingolimod binds to the S1P receptor on lymphocytes and, by reducing its expression, prevents lymphocytes from exiting lymphatic tissue. This mechanism inhibits the migration of autoreactive lymphocytes into the CNS and the development of inflammatory changes. Fingolimod crosses the blood-brain barrier (BBB) and has a neuroprotective effect.

Keywords: INF-beta-1b, INF-beta-1a, glatiramer acetate, treatment escalation, fingolimod

Published: December 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Taláb R, Talábová M. Fingolimod in clinical practice: case reports. Neurol. praxi. 2014;15(6):333-337.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barkhof F, De Jong R, Sfikas N, de Vera A, Gordon F, Cohen J and on behalf. of the TRANSFORM study group. The influence of patient demographicsm disease characteristics and treatment on brain volume loss in Trial Assesing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. MSJ 2014. http://www.sagepub.co.uk/journalsPermisions.nav. Go to original source... Go to PubMed...
    2. Calabresi PA, Radue EW, Jeffery D, Rammohan K, Reder AT, Vollmer T, Kappos L, Agius M a S, Tracy L, Bingbing C, Linda von Rosenstiel, Lublin P, Fred D. Safety and efficacy of fingolimod in patients with relapsing-remitting scerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology 2014; published online March 28: http://dx.doi.org/10.1016/S1474-4422(14)70049-3. Go to original source... Go to PubMed...
    3. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. Oral fingolimod or inramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415. Go to original source... Go to PubMed...
    4. Havrdová E. Současné možnosti léčby roztroušené sklerózy. Remedia 2010; 20: 278-282.
    5. Kappos L, Cohen J, Colins W, de Vera A, Zhang-Auberson L, Ritter S, von Rosenstiel P, Francis G. Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Multiple Sclerosis and Related Disorders 2014. Go to original source...
    6. Kappos L, Radue EW, O´Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. Group FREEDOMS Study. A placebo-controlled trial of oral fingolimod in relapsing mutiple sclerosis. N Engl J Med 2010; 362: 387-401. Go to original source... Go to PubMed...
    7. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008; 255(10): 1449-1463. Go to original source... Go to PubMed...
    8. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Moltaban X, O´Connor P, Sandberg-Wolheim M, Thompson AJ, Waubant A, Weinshenker B, Wolinsky JS. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. ANN Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
    9. Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scle 2012; 18: 143-152. Go to original source... Go to PubMed...
    10. Taláb R. Dlouhodobá léčba roztroušené sklerózy mozkomíšní a lékový switch. ACTA MEDICINAE; 1/2013: 40-44.
    11. Taláb R, Talábová M. Biologická léčba roztroušené sklerózy. ACTA MEDICINAE; 1/2014: 55-60.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.